BR112022024533A2 - Formulação compreendendo daprodustat - Google Patents
Formulação compreendendo daprodustatInfo
- Publication number
- BR112022024533A2 BR112022024533A2 BR112022024533A BR112022024533A BR112022024533A2 BR 112022024533 A2 BR112022024533 A2 BR 112022024533A2 BR 112022024533 A BR112022024533 A BR 112022024533A BR 112022024533 A BR112022024533 A BR 112022024533A BR 112022024533 A2 BR112022024533 A2 BR 112022024533A2
- Authority
- BR
- Brazil
- Prior art keywords
- daprodustat
- formulation including
- immediate release
- release tablet
- aspects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
FORMULAÇÃO COMPREENDENDO DAPRODUSTAT. A presente divulgação refere-se a um comprimido de liberação imediata de daprodustat com resistência à tração satisfatória. Em outros aspectos, usos médicos do comprimido de liberação imediata e regimes de dosagem para usar o comprimido de liberação imediata são divulgados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063041403P | 2020-06-19 | 2020-06-19 | |
US202063043292P | 2020-06-24 | 2020-06-24 | |
PCT/EP2021/066386 WO2021255159A1 (en) | 2020-06-19 | 2021-06-17 | Formulation comprising daprodustat |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022024533A2 true BR112022024533A2 (pt) | 2022-12-27 |
Family
ID=76730508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022024533A BR112022024533A2 (pt) | 2020-06-19 | 2021-06-17 | Formulação compreendendo daprodustat |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230225977A1 (pt) |
EP (1) | EP4167967A1 (pt) |
JP (1) | JP2023532223A (pt) |
CN (1) | CN115697307A (pt) |
BR (1) | BR112022024533A2 (pt) |
CA (1) | CA3180509A1 (pt) |
WO (1) | WO2021255159A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4355734A1 (en) * | 2021-06-18 | 2024-04-24 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Novel manufacturing method of daprodustat and precursors thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20080209A1 (es) | 2006-06-23 | 2008-05-15 | Smithkline Beecham Corp | Derivados de glicina como inhibidores de prolil hidroxilasa |
CN101773498B (zh) * | 2009-12-30 | 2012-06-20 | 青岛黄海制药有限责任公司 | 一种含有非布司他的口服缓控释制剂的制备方法 |
CN108135854B (zh) * | 2015-06-30 | 2022-03-11 | 基因泰克公司 | 含有药物的立即释放片剂和用于形成片剂的方法 |
EP3682884B1 (en) * | 2017-09-15 | 2024-04-24 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Crystalline forms of daprodustat (gsk1278863), a peroral hypoxia-inducible factor prolyl hydroxylase inhibitor (hif-phi) for treating anemia, and their preparation methods |
WO2019067634A1 (en) * | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | NIRAPARIB FORMULATIONS |
EP3880663A1 (en) * | 2018-11-15 | 2021-09-22 | Teva Pharmaceuticals International GmbH | Solid state forms of daprodustat and process for preparation thereof |
-
2021
- 2021-06-17 CN CN202180043608.0A patent/CN115697307A/zh active Pending
- 2021-06-17 BR BR112022024533A patent/BR112022024533A2/pt unknown
- 2021-06-17 US US18/010,245 patent/US20230225977A1/en active Pending
- 2021-06-17 EP EP21736531.1A patent/EP4167967A1/en active Pending
- 2021-06-17 WO PCT/EP2021/066386 patent/WO2021255159A1/en unknown
- 2021-06-17 CA CA3180509A patent/CA3180509A1/en active Pending
- 2021-06-17 JP JP2022577794A patent/JP2023532223A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115697307A (zh) | 2023-02-03 |
WO2021255159A1 (en) | 2021-12-23 |
EP4167967A1 (en) | 2023-04-26 |
US20230225977A1 (en) | 2023-07-20 |
CA3180509A1 (en) | 2021-12-23 |
JP2023532223A (ja) | 2023-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016027773A2 (pt) | peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica | |
BR112016028672A2 (pt) | análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo | |
BR112016007479A2 (pt) | regimes de dosagem de imunoconjugado de anti-folr1 | |
BR112015028244A2 (pt) | Imunoconjugado que se liga ao folr1 e seu uso | |
CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
ECSP17077930A (es) | Métodos y kits para tratar la depresión | |
CR20120349A (es) | Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados | |
CL2008001268A1 (es) | Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor. | |
AR063760A1 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
BRPI0617294B8 (pt) | composição farmacêutica em gel hidroalcóolico e uso de testosterona | |
ECSP12011735A (es) | Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor | |
BR112014010699A2 (pt) | administração de inibidor de enzima de ativação de nedd8 e agente de hipometilação | |
BR112023000909A2 (pt) | Composições de alvejamento muscular engenheiradas | |
BR112022024533A2 (pt) | Formulação compreendendo daprodustat | |
BRPI0513938B8 (pt) | composição farmacêutica contendo drospirenona e etinilestradiol | |
BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
BR112014021602A2 (pt) | uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide | |
AR094289A1 (es) | Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol | |
CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
BR112014027047A2 (pt) | nova formulação | |
BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
MX2020004516A (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas. | |
BR112023019668A2 (pt) | Composição farmacêutica para prevenir ou tratar fibrose |